Antibody to Cryptococcus neoformans Glucuronoxylomannan Inhibits the Release of Capsular Antigen

ABSTRACT Cryptococcus neoformans releases capsular polysaccharide in the supernatant of liquid cultures and in tissues. Significantly less glucuronoxylomannan (GXM) was released by C. neoformans in the presence of capsule-binding monoclonal antibody (MAb). MAb-mediated inhibition of GXM release may be another mechanism by which humoral immunity can mediate protection against this pathogen.

[1]  A. Casadevall,et al.  Induction of Capsule Growth in Cryptococcus neoformans by Mammalian Serum and CO2 , 2003, Infection and Immunity.

[2]  Arturo Casadevall,et al.  Antibody-mediated regulation of cellular immunity and the inflammatory response. , 2003, Trends in immunology.

[3]  L. Weinhold,et al.  In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. , 2001, The Journal of infectious diseases.

[4]  A. Vecchiarelli,et al.  Immunoregulation by capsular components of Cryptococcus neoformans. , 2000, Medical mycology.

[5]  Arturo Casadevall,et al.  Antibody Interactions with the Capsule ofCryptococcus neoformans , 2000, Infection and Immunity.

[6]  A. Casadevall,et al.  Biological Correlates of Capsular (Quellung) Reactions of Cryptococcus neoformans1 , 2000, The Journal of Immunology.

[7]  A. Casadevall,et al.  Organ-Dependent Variation of Capsule Thickness inCryptococcus neoformans during Experimental Murine Infection , 1998, Infection and Immunity.

[8]  A. Casadevall,et al.  Characterization of a Murine Monoclonal Antibody toCryptococcus neoformans Polysaccharide That Is a Candidate for Human Therapeutic Studies , 1998, Antimicrobial Agents and Chemotherapy.

[9]  A. Casadevall,et al.  Epitope Location in the Cryptococcus neoformans Capsule Is a Determinant of Antibody Efficacy , 1997, The Journal of experimental medicine.

[10]  A. Casadevall,et al.  Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme-linked immunosorbent spot assay for detection of mycobacteria , 1996, Journal of clinical microbiology.

[11]  A. Casadevall,et al.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody , 1995, Infection and immunity.

[12]  A. Casadevall,et al.  Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell , 1995, The Journal of experimental medicine.

[13]  R. Cherniak,et al.  Polysaccharide antigens of the capsule of Cryptococcus neoformans , 1994, Infection and immunity.

[14]  A. Casadevall,et al.  Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B , 1994, Antimicrobial Agents and Chemotherapy.

[15]  A. Casadevall,et al.  Protective murine monoclonal antibodies to Cryptococcus neoformans , 1992, Infection and immunity.

[16]  A. Casadevall,et al.  Monoclonal antibody based ELISAs for cryptococcal polysaccharide. , 1992, Journal of immunological methods.

[17]  A. Casadevall,et al.  Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. , 1992, The Journal of infectious diseases.

[18]  A. Casadevall,et al.  The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies , 1991, The Journal of experimental medicine.

[19]  J. Perfect,et al.  Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. , 1985, The Journal of clinical investigation.

[20]  T. Rothstein,et al.  Affinity analysis of idiotype-positive and idiotype-negative Ars-binding hybridoma proteins and Ars-immune sera. , 1983, Molecular immunology.

[21]  S Ie,et al.  Cryptococcus neoformans. , 1998, The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society.